Press Releases
BioVentrix® Closes $48.5 Million Series A Financing
Financing led by Andera Partners including Cormorant Asset Management, Taglich Brothers Inc., Squarepoint Capital, and Richmond Brothers to Support Premarket Approval of Revivent TC® System for Patients with Ischemic Heart Failure MANSFIELD, MA – April 13, 2023 – BioVentrix, Inc., a privately held medical device company developing minimally invasive therapies [...]
New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC® Therapy
Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device Therapy MANSFIELD, MA, USA – March 15, 2023 – BioVentrix®, Inc., a privately held medical device company developing less invasive therapies to directly treat the dilated left ventricle leading to progressive heart failure, today announced the publication of a peer-reviewed [...]
BioVentrix Names Dr. Ori Ben-Yehuda as Chief Medical Officer
Brings Extensive Clinical Trial and Patient Care Experience to Senior Management Team SAN RAMON, Calif. – February 08, 2023 – BioVentrix, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process [...]
FDA Agrees to Expanded Access Program for the BioVentrix Revivent TC® System for the Treatment of Ischemic Heart Failure
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif. – January 24, 2023 – BioVentrix, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process [...]
BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.
Revolutionary Heart Failure Therapy Company Also Adds New Executive and Well-Known Board Member to Enhance Expertise SAN RAMON, Calif. – January 27, 2022 - BioVentrix, Inc., a privately held medical device company focused on less invasive therapies to treat the left ventricle (LV), known to be the root [...]
BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of Directors
SAN RAMON, Calif. – July 21, 2021 – BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company’s chairman and named Rinda K. Sama and Andrew G. Hinson to its [...]
BioVentrix Names Jim Dillon President and CEO
Proven Leader Will Take Revolutionary Heart Failure Therapy Company to Next LevelSAN RAMON, Calif. - April 29, 2021. BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter-based Ventricular Restoration (TCVR), today announced that Jim Dillon has been named President and CEO.In his [...]
Kardio-Tech-Firma aus Kalifornien gründet Deutschland-Niederlassung und macht so innovative Herztherapie breiter verfügbar
San Ramon, Kalifornien, und Hilden bei Düsseldorf, 19. Februar 2021„Bringing innovation in cardiology from California to Germany.“ So könnte die Überschrift einer der jüngsten Firmengründungen in der Medizintechnik-Branche in Deutschland lauten. BioVentrix Inc. ist ein in Privatbesitzt befindliches Unternehmen mit Hauptsitz im kalifornischen San Ramon (USA). Die Firma wurde 2007 [...]
BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System
SAN RAMON, Calif. – February 8, 2021 - BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for [...]
BioVentrix Announces Jerry Estep, MD, as Co-Principal Investigator for ALIVE Pivotal Trial Studying a Transcatheter Device for Heart Failure
SAN RAMON, Calif. – January 6, 2021 – BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE [...]
BioVentrix Announces the Appointment of Cardiac Device Veteran Chris Wolff as Vice President of U.S. Sales
San Ramon, CA, USA – October 5, 2020 – BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that Chris Wolff has been named Vice President of U.S. Sales. In this role, Mr. Wolff will be responsible [...]
Neuartige Herzoperation in Tübingen durchgeführt
Das Tübinger Herzzentrum hat nach einer Corona-bedingten Zwangspause erfolgreich einen Herzschwäche-Patienten mit einem neuartigen Verfahren behandelt. Dabei wurde die linke Herzkammer verkleinert. Der 60-Jährige wurde nach einem Herzinfarkt immer schwächer. Zuletzt konnte er nur noch wenige Schritte ohne Pause gehen.Nach der Operation mit der minimalinvasiven Methode gehe es dem Patienten [...]
Kasuistik zur Postinfarkt-Herzinsuffizienz publiziert
January 27, 2022 Erfolgreiches minimalinvasives Postmyokardinfarkt-Verfahren führt zu einem Anstieg der linksventrikulären Ejektionsfraktion von 20 auf 35%Patienten nach Myokardinfarkt entwickeln trotz leitliniengerechter Herzinsuffizienz-Therapien (GDMT, guideline-directed medical therapy) oft fortschreitende Herzinsuffizienz-Symptome.Nun wurde im European Heart Journal eine Kasuistik publiziert, in der ein Patient mit Postinfarkt-Herzinsuffizienz mit dem Revivent TC™-System behandelt wurde.1Dabei [...]
BioVentrix Announces Pivotal ALIVE Trial Resumes with First Patients Treated with LIVE Therapy Since COVID-19 Pause
San Ramon, Calif. – September 2, 2020 – BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that the Company has resumed cases in the pivotal ALIVE Trial studying Less Invasive Ventricular Enhancement, or LIVE™ Therapy, using the Revivent TC™ [...]
BioVentrix Announces Appointment of Accredited Public Company Director, Raymond W. Cohen, to its Board of Directors
SAN RAMON, Calif. – August 12, 2020 – BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen to the Company’s board of directors.Mr. Cohen, an accredited public company director, has nearly 40 [...]